Disc Medicine COO exercises options and sells shares

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Operating Officer Yu Jonathan Yen-Wen exercised stock options for 804 shares of common stock at an exercise price of $13.50 per share and sold 804 shares of common stock at a weighted average price of $82.6425 per share, with individual sale prices ranging from $82.54 to $82.83. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. Following the option exercise, he held 22,943 option shares tied to this grant, which vests in 48 equal monthly installments after December 29, 2022 and expires on December 28, 2032.

Insider Trade Summary 10b5-1

Exercise and Sale: 804 shares ($56K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Yu Jonathan Yen-Wen

Role Chief Operating Officer

Sold 804 shs ($66K)

Approx. gross sale proceeds $66K

Approx. exercise cost $11K

Approx. pre-tax spread $56K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	804	$0.00	$0.00
Exercise	Common Stock F1	804	$13.50	$11K
Sale	Common Stock F1, F2	804	$82.6425	$66K

Holdings After Transaction: Stock Option (Right to Buy) — 22,943 contracts (Direct); Common Stock — 54,324 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.54 to $82.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
3. F3. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 804 shares Weighted average sale price: $82.6425 per share Option exercise price: $13.50 per share +4 more

7 metrics

Shares sold 804 shares Common stock sold on August 12, 2026

Weighted average sale price $82.6425 per share Common stock sales ranging from $82.54 to $82.83

Option exercise price $13.50 per share Stock Option (Right to Buy) for 804 shares

Options remaining 22,943 shares Option shares held after exercising 804 shares

Option vesting schedule 48 equal monthly installments Vesting following December 29, 2022

Option expiration date December 28, 2032 Expiration of the Stock Option (Right to Buy)

10b5-1 plan adoption date March 17, 2026 Rule 10b5-1 trading plan governing these transactions

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vesting financial

"shares underlying this option vest in 48 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IRON’s COO Yu Jonathan Yen-Wen report in this Form 4?

He exercised options for 804 shares at $13.50 per share and sold 804 shares of Disc Medicine common stock at a weighted average price of $82.6425 per share on August 12, 2026.

Was the IRON insider transaction done under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on March 17, 2026, indicating they were pre-arranged rather than discretionary trades on that date.

How many Disc Medicine (IRON) shares did the COO sell and at what price?

He sold 804 shares of Disc Medicine common stock at a weighted average price of $82.6425 per share, with individual sale prices ranging from $82.54 to $82.83, according to the Form 4 footnote.

What options did the IRON COO exercise in this Form 4 filing?

He exercised a Stock Option (Right to Buy) covering 804 shares of common stock at an exercise price of $13.50 per share. This option grant vests in 48 equal monthly installments after December 29, 2022.

How many Disc Medicine (IRON) option shares does the COO hold after this exercise?

After exercising 804 option shares, the reporting person held 22,943 option shares tied to this grant. The option is scheduled to expire on December 28, 2032, as disclosed in the Form 4 data.

What is the nature of the IRON insider’s remaining derivative position?

The remaining derivative position is a stock option for 22,943 underlying shares of Disc Medicine common stock, vesting monthly and scheduled to expire on December 28, 2032, with an exercise price of $13.50 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 07:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Jonathan Yen-Wen

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		M(1)		804	A	$13.5	55,128	D
Common Stock	08/12/2026		S(1)		804	D	$82.6425(2)	54,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.5	08/12/2026		M(1)			804	(3)	12/28/2032	Common Stock	804	$0	22,943	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.54 to $82.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

3. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

	By: /s/ Rahul Khara, as Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)